Free Trial

Delcath Systems (DCTH) Competitors

Delcath Systems logo
$11.10 +0.30 (+2.78%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$11.10 0.00 (0.00%)
As of 10/8/2025 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DCTH vs. CDRE, CNMD, SSII, PLSE, KMTS, BLFS, ESTA, MDXG, TNDM, and BBNX

Should you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include Cadre (CDRE), CONMED (CNMD), SS Innovations International (SSII), Pulse Biosciences (PLSE), Kestra Medical Technologies (KMTS), BioLife Solutions (BLFS), Establishment Labs (ESTA), MiMedx Group (MDXG), Tandem Diabetes Care (TNDM), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

Delcath Systems vs. Its Competitors

Delcath Systems (NASDAQ:DCTH) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 17.4% of Delcath Systems shares are owned by company insiders. Comparatively, 31.5% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Delcath Systems currently has a consensus target price of $24.50, suggesting a potential upside of 120.72%. Cadre has a consensus target price of $31.50, suggesting a potential downside of 18.35%. Given Delcath Systems' stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than Cadre.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Cadre
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cadre has higher revenue and earnings than Delcath Systems. Cadre is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delcath Systems$37.21M10.43-$26.39M$0.05222.00
Cadre$567.56M2.76$36.13M$0.9441.04

Cadre has a net margin of 6.65% compared to Delcath Systems' net margin of 3.18%. Cadre's return on equity of 12.08% beat Delcath Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Delcath Systems3.18% 6.91% 5.80%
Cadre 6.65%12.08%5.60%

In the previous week, Delcath Systems had 2 more articles in the media than Cadre. MarketBeat recorded 6 mentions for Delcath Systems and 4 mentions for Cadre. Delcath Systems' average media sentiment score of 0.27 beat Cadre's score of -0.08 indicating that Delcath Systems is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Delcath Systems
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cadre
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Delcath Systems has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Cadre has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Summary

Delcath Systems beats Cadre on 9 of the 16 factors compared between the two stocks.

Get Delcath Systems News Delivered to You Automatically

Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DCTH vs. The Competition

MetricDelcath SystemsMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$377.80M$6.99B$6.09B$10.54B
Dividend YieldN/A1.16%5.69%4.71%
P/E Ratio222.0027.6685.3527.60
Price / Sales10.43195.36539.78202.41
Price / CashN/A21.7337.9261.55
Price / Book5.165.4513.016.76
Net Income-$26.39M$178.04M$3.30B$275.88M
7 Day Performance4.23%4.21%4.34%2.81%
1 Month Performance-4.31%12.27%9.49%9.24%
1 Year Performance30.43%34.25%84.83%35.42%

Delcath Systems Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DCTH
Delcath Systems
2.638 of 5 stars
$11.10
+2.8%
$24.50
+120.7%
+31.5%$377.80M$37.21M222.0060Analyst Forecast
CDRE
Cadre
2.1731 of 5 stars
$37.54
+2.4%
$31.50
-16.1%
-1.3%$1.49B$567.56M39.932,284News Coverage
Analyst Forecast
CNMD
CONMED
4.6281 of 5 stars
$46.42
-3.6%
$59.80
+28.8%
-27.2%$1.49B$1.31B13.153,900Analyst Forecast
SSII
SS Innovations International
N/A$6.80
-5.4%
N/AN/A$1.39B$20.65M0.004Analyst Forecast
PLSE
Pulse Biosciences
3.193 of 5 stars
$19.45
+0.8%
$22.00
+13.1%
+26.3%$1.30B$700K-18.52140Analyst Forecast
KMTS
Kestra Medical Technologies
1.1152 of 5 stars
$25.03
+0.8%
$27.33
+9.2%
N/A$1.28B$59.81M0.00300Analyst Forecast
BLFS
BioLife Solutions
2.1074 of 5 stars
$26.52
-0.3%
$31.29
+18.0%
+15.2%$1.27B$82.25M-220.98440Positive News
Analyst Forecast
ESTA
Establishment Labs
2.7699 of 5 stars
$39.33
-5.1%
$56.50
+43.7%
-5.6%$1.20B$166.02M-12.901,018News Coverage
Positive News
Analyst Forecast
MDXG
MiMedx Group
3.3822 of 5 stars
$7.31
+1.4%
$12.00
+64.2%
+26.8%$1.07B$348.88M34.81870Positive News
Analyst Forecast
High Trading Volume
TNDM
Tandem Diabetes Care
4.1696 of 5 stars
$15.01
+2.0%
$22.44
+49.5%
-61.5%$993.95M$940.20M-4.862,650Analyst Forecast
BBNX
Beta Bionics
1.9425 of 5 stars
$21.95
-1.4%
$24.44
+11.4%
N/A$967.65M$65.12M0.00294Analyst Forecast
Insider Trade

Related Companies and Tools


This page (NASDAQ:DCTH) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners